SanjivSAgarwalaMD

Oncology • Bethlehem, PA

Chief of medical oncology and hematology at St. Luke

Join to view full profile

Dr. Agarwala is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Agarwala's full profile

Already have an account?

Office
801 Ostrum St
Bethlehem, PA 18015
Phone+1 484-526-2140

Fax+1 484-526-6055

Education & Training

UPMC Medical EducationResidency, Internal Medicine, 1992 - 1993
UPMC Medical EducationFellowship, Hematology and Medical Oncology, 1990 - 1991
Seth G.S. Medical CollegeClass of 1984

Certifications & Licensure

PA State Medical License 1993 - 2024
WI State Medical License 1993 - 1995
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2013

Clinical Trials

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma Start of enrollment: 1999 Mar 25
Active, not recruiting
Phase 3
FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma Start of enrollment: 2005 Oct 04
Terminated
Phase 2
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Start of enrollment: 2006 Sep 15
Completed
Phase 2
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 3
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 15
Active, not recruiting
Phase 2
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma Start of enrollment: 2009 Nov 17
Active, not recruiting
Phase 3
A Study to Assess PV-10 Chemoablation of Cancer of the Liver Start of enrollment: 2009 Oct 01
Active, not recruiting
Phase 1
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy Start of enrollment: 2011 Jan 18
Completed
Phase 2
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Start of enrollment: 2010 Apr 12
Active, not recruiting
Phase 3
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Start of enrollment: 2010 Sep 21
Active, not recruiting
Phase 2
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2011 May 16
Completed
Not Applicable
Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors
No longer available
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25
Active, not recruiting
Phase 3
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Start of enrollment: 2011 Sep 06
Completed
Phase 1, Phase 2
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
Completed
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2012 Jun 03
Completed
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Start of enrollment: 2012 Aug 01
Terminated
Phase 4
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
Completed
Phase 3
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2013 Oct 14
Completed
Phase 2
MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
Completed
Phase 2
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Sep 16
Active, not recruiting
Phase 3
A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck Start of enrollment: 2013 Aug 01
Completed
Phase 1
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors Start of enrollment: 2017 Jun 09
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

4 citations
Systemic Therapy for Melanoma: ASCO Guideline Update Q and A.
Vernon K Sondak, Michael B Atkins, Hans Messersmith, Anthony Provenzano, Rahul Seth
JCO Oncology Practice. 2024-02-01
32 citations
Systemic Therapy for Melanoma: ASCO Guideline Update.
Rahul Seth, Sanjiv S Agarwala, Hans Messersmith, Krishna C Alluri, Paolo A Ascierto
Journal of Clinical Oncology. 2023-10-20
2 citations
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).
Paolo A Ascierto, Sanjiv S Agarwala, Allison Betof Warner, Marc S Ernstoff, Bernard A Fox
Journal of Translational Medicine. 2023-07-28

Lectures

Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma progressing on or after a PD-1/L1 blocking antibody.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Groundbreaking Trial by Indian American Researcher Sanjiv Agarwala Sees Cancerous Tumors ‘Flake Off’July 3rd, 2019
Cancerous Tumors Flake off After Injection of Exotic ‘Rose Bengal’ in Groundbreaking St. Luke’s TrialJune 27th, 2019
Optimizing Adjuvant Strategies Extends RFS in High-Risk MelanomaMarch 11th, 2019
Join now to see all

Grant Support

Ph1 Stdy Epidermal Grwth FCT REC Tyrosine Kinase INH Combo W/DocetaxelNational Center For Research Resources2005
PH II UCN-01 Metastatic MelanomaNational Center For Research Resources2005
PHI Dose Escal. Study Eval Safety Of AlbuleukinNational Center For Research Resources2004
Ph3, Mc, Ol, Surv/Safety Study Of Head/Neck CarcinomaNational Center For Research Resources2004
Ph1 Study EGFR Tyrosine Kinase Inhibitor W/ DocetaxelNational Center For Research Resources2004
A RAND Study Of Four Weeks High Dose IFN 2B In MelanomaNational Center For Research Resources2004
Four Week High Dose Interferon A2B In Stage IIA MelanomaNational Center For Research Resources2000–2002
Phase II Study Of Temozolomide (SCH52365) Prior To Radiation TherapyNational Center For Research Resources1997–2002
Phase I Study Of Recurrent Or Metastatic Squamous Cell Carcinoma Of Head/NeckNational Center For Research Resources1997–2002
Temozolomide In Treatment Of Metastatic Melanoma W/ Brain MetastasesNational Center For Research Resources1999–2000
Recombinant Keratinocyte Growth Factor For Head &Neck CancerNational Center For Research Resources1999–2000
OPEN Label Randomized Study To Eval Effect Safety Of 2 TreatmentsNational Center For Research Resources1999–2000
Phase II Study Of Suramin In Patients With Metastatic MelanomaNational Center For Research Resources1997–2000
Temozolomide Treatment In Metastatic Melanoma With Brain MetastasesNational Center For Research Resources1999
Phase II Study To Evaluate Safety Of Two Treatment Regimes For Head/Neck CancerNational Center For Research Resources1999
Phase I/II Study Of Recombinant Keratinocyte Growth Factor In Head/Neck CancerNational Center For Research Resources1999
Phase I Study Of Temozolomide In Combo With Cisplatin In Advanced Cancer PTSNational Center For Research Resources1998–1999
Phase I Study Of Temozolomide In Combination With Cisplatin In Advanced CancerNational Center For Research Resources1997
Phase II Trial Of Topotecan In Patients With Metastatic Squamous CarcinomaNational Center For Research Resources1996–1997